29 October 2026 Quarterly Activities Report and Appendix 4C For the period ended 30 September 2026 Key Milestones Achieved as Patrys Successfully Completes Cohort 1 Dosing in RLS-2202 Phase 1a Trial Highlights: • Human Research Ethics Committee (HREC) approval secured and first participants dosed...
Appendix 4C - Quarterly - 30 September 2026
Filed with ASX · · 9 pages · English
Release
Story so far
Earlier from Patrys
- RLS-2202 Phase 1a Trial Advances to Cohort 2
- Investor Presentation
- Investor Webinar
- Date of AGM and Closing Date for Director Nominations
- Notification of cessation of securities - PAB
Later from Patrys
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders - Annual General Meeting
- Application for quotation of securities - PAB
- Cleansing Notice
- Change of Director's Interest Notice x2
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys